Last reviewed · How we verify
Tolectin 600 (TOLMETIN)
Tolectin 600 (Tolmetin) is a nonsteroidal anti-inflammatory drug (NSAID) developed by a predecessor of Ortho McNeil Janssen. It targets prostaglandin G/H synthase 2, a key enzyme in the inflammatory process. Tolmetin is used to treat juvenile rheumatoid arthritis, osteoarthritis, and rheumatoid arthritis. The drug is now off-patent, with multiple generic manufacturers available. As an NSAID, it carries the typical risks associated with this class, including gastrointestinal and renal side effects.
At a glance
| Generic name | TOLMETIN |
|---|---|
| Sponsor | Ortho Mcneil Janssen |
| Drug class | Nonsteroidal Anti-inflammatory Drug |
| Target | Prostaglandin G/H synthase 2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1976 |
Approved indications
- Juvenile rheumatoid arthritis
- Osteoarthritis
- Rheumatoid arthritis
Boxed warnings
- Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS and PRECAUTIONS ). TOLECTIN capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS and WARNINGS ). Gastrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS ).
Common side effects
- nausea
- dyspepsia
- gastrointestinal distress
- abdominal pain
- diarrhea
- flatulence
- vomiting
- constipation
- gastritis
- peptic ulcer
- headache
- asthenia
Drug interactions
- warfarin
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tolectin 600 CI brief — competitive landscape report
- Tolectin 600 updates RSS · CI watch RSS